William O’Riordan
About
William O’Riordan is a scholar working on Infectious Diseases, Clinical Biochemistry and Public Health, Environmental and Occupational Health.
According to data from OpenAlex, William O’Riordan has authored 38 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 20 papers in Clinical Biochemistry and 10 papers in Public Health, Environmental and Occupational Health. Recurrent topics in William O’Riordan's work include Antimicrobial Resistance in Staphylococcus (23 papers), Bacterial Identification and Susceptibility Testing (20 papers) and Streptococcal Infections and Treatments (10 papers). William O’Riordan is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (23 papers), Bacterial Identification and Susceptibility Testing (20 papers) and Streptococcal Infections and Treatments (10 papers). William O’Riordan collaborates with scholars based in United States, Spain and United Kingdom. William O’Riordan's co-authors include G. Ralph Corey, Steven L. Barriere, Michael M. Kitt, Vance G. Fowler, Martín E. Stryjewski, G. Ralph Corey, Samantha Good, Greg Moeck, Hai Jiang and J. Scott Overcash and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Blood.
In The Last Decade
William O’Riordan
36 papers receiving 1.7k citations
Peers
William O’Riordan
Luis Felipe Reyes Colombia
Matthaios Papadimitriou‐Olivgeris Switzerland
J. Blaser Switzerland
Barry Hafkin United States
Laura Morata Spain
Arnold Lentnek United States
Sun Young Cho South Korea
Bert K. Lopansri United States
Sébastien Tanaka France
J.P. Thys Belgium
Citations per year, relative to William O’Riordan William O’Riordan (= 1×)
peers
Luis Felipe Reyes
Countries citing papers authored by William O’Riordan
Since
Specialization
Citations
This map shows the geographic impact of William O’Riordan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William O’Riordan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William O’Riordan more than expected).
Fields of papers citing papers by William O’Riordan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by William O’Riordan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William O’Riordan. The network helps show where William O’Riordan may publish in the future.
Co-authorship network of co-authors of William O’Riordan
This figure shows the co-authorship network connecting the top 25 collaborators of William O’Riordan. A scholar is included among the top collaborators of William O’Riordan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William O’Riordan. William O’Riordan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
O’Riordan, William, Lynne Garrity-Ryan, Anita Das, et al.. (2019). Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. The Lancet Infectious Diseases. 19(10). 1080–1090.
2.
Lv, Xiaoju, Jeff Alder, Li Li, et al.. (2019). Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection. Antimicrobial Agents and Chemotherapy. 63(7).
3.
Adams, David, Alejandra González‐Duarte, William O’Riordan, et al.. (2018). Evaluation of Quality of Life and Disability in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy Following Treatment with Patisiran, An Investigational RNAi Therapeutic: Results from the Phase 3 APOLLO Study (S31.003). Neurology. 90(15_supplement).
4.
González‐Duarte, Alejandra, David Adams, William O’Riordan, et al.. (2018). Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment : Analysis from APOLLO. Journal of the Peripheral Nervous System. 23(4). 400–400.
5.
Huang, David B., G. Ralph Corey, Thomas L Holland, et al.. (2018). Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. International Journal of Antimicrobial Agents. 52(2). 233–240.
6.
O’Riordan, William, et al.. (2017). Outcomes with IV/oral Delafloxacin (DLX) Compared with Vancomycin/Aztreonam (VAN/AZ) in Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Gram-negative (GN) Pathogens. Open Forum Infectious Diseases. 4(suppl_1). S532–S532.
7.
Corey, G. Ralph, Francis F. Arhin, Matthew A. Wikler, et al.. (2016). Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents. 48(5). 528–534.
8.
O’Riordan, William, Courtney Tiffany, Nicole E. Scangarella-Oman, et al.. (2016). Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in Patients With Acute Bacterial Skin and Soft Structure Infections from a Phase 2 Randomized, Adaptive-Design, Dose-Ranging Study. Open Forum Infectious Diseases. 3(suppl_1).
9.
Corey, G. Ralph, Samantha Good, Hai Jiang, et al.. (2014). Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study. Clinical Infectious Diseases. 60(2). 254–262.
10.
Corey, G. Ralph, Heidi Kabler, Purvi Mehra, et al.. (2014). Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. New England Journal of Medicine. 370(23). 2180–2190.
11.
O’Riordan, William, et al.. (2014). A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. International Journal of Infectious Diseases. 30. 67–73.
12.
Vince, Bradley, John M. Hill, Eric Lawitz, et al.. (2014). A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. Journal of Hepatology. 60(5). 920–927.
13.
Stryjewski, Martín E., Arnold Lentnek, William O’Riordan, et al.. (2014). A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infectious Diseases. 14(1). 289–289.
14.
Lalezari, Jacob, Terry Box, William O’Riordan, et al.. (2013). Idx184 in Combination with Pegylated Interferon-α2A and Ribavirin for 2 Weeks in Treatment-Naive Patients with Chronic Hepatitis C. Antiviral Therapy. 18(6). 755–764.
15.
Stryjewski, Martín E., Donald R. Graham, Samuel E. Wilson, et al.. (2008). Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms. Clinical Infectious Diseases. 46(11). 1683–1693.
16.
Wilson, Samuel E., William O’Riordan, Alan R. Hopkins, et al.. (2008). Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. The American Journal of Surgery. 197(6). 791–796.
17.
Stryjewski, Martín E., Russell P. Hall, Vivian H. Chu, et al.. (2007). Expression of Antimicrobial Peptides in the Normal and Involved Skin of Patients with Infective Cellulitis. The Journal of Infectious Diseases. 196(9). 1425–1430.
18.
Sherman, David G., Gregory W. Albers, Christopher Bladin, et al.. (2007). The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. The Lancet. 369(9570). 1347–1355.
19.
Sherman, David G., Gregory W. Albers, Christopher Bladin, et al.. (2006). Prevention of Venous Thromboembolism after Acute Ischemic Stroke with Enoxaparin Versus Unfractionated Heparin and the Impact of Stroke Severity.. Blood. 108(11). 713–713.
20.
O’Riordan, William & Neil J. Sherman. (1977). Cryptorchidism and abdominal pain. Journal of the American College of Emergency Physicians. 6(5). 196–197.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Luis Felipe Reyes Breakdown of academic impact, for papers by Matthaios Papadimitriou‐Olivgeris Breakdown of academic impact, for papers by J. Blaser Breakdown of academic impact, for papers by Barry Hafkin Breakdown of academic impact, for papers by Laura Morata Breakdown of academic impact, for papers by Arnold Lentnek Breakdown of academic impact, for papers by Sun Young Cho Breakdown of academic impact, for papers by Bert K. Lopansri Breakdown of academic impact, for papers by Sébastien Tanaka Breakdown of academic impact, for papers by J.P. Thys